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ABSTRACT Pemphigus is a group of rare and life-threatening autoimmune blistering dis-
eases of the skin and mucous membranes. Although they occur worldwide, their incidence 
shows wide geographical variation, and prospective data on the epidemiology of pemphi-
gus are very limited. Objective of this work is to evaluate the incidence and epidemiological 
and clinical features of patients with pemphigus in Turkey. All patients newly diagnosed with 
pemphigus between June 2013 and June 2014 were prospectively enrolled in 33 dermatol-
ogy departments in 20 different provinces from all seven regions of Turkey. Disease param-
eters including demography and clinical findings were recorded. A total of 220 patients were 
diagnosed with pemphigus during the 1-year period, with an annual incidence of 4.7 per 
million people in Turkey. Patients were predominantly women, with a male to female ratio of 
1:1.41. The mean age at onset was 48.9 years. Pemphigus vulgaris (PV) was the commonest 
clinical subtype (n=192; 87.3%), followed by pemphigus foliaceus (n=21; 9.6%). The most 
common clinical subtype of PV was the mucocutaneous type (n=83; 43.2%). The mean Pem-
phigus Disease Area index was 28.14±22.21 (mean ± Standard Deviation).  The incidence 
rate of pemphigus in Turkey is similar to the countries of South-east europe, higher than 
those reported for the Central and northern european countries and lower than the coun-
tries around the Mediterranean Sea and iran. Pemphigus is more frequent in middle-aged 
people and is more common in women. The most frequent subtype was PV, with a 9-fold 
higher incidence than pemphigus foliaceus. 
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INTRODUCTION
Pemphigus is a group of rare and life-threatening 
autoimmune bullous diseases of the skin and mucous 
membranes which result in intraepidermal blistering. 
it is associated with pathogenic antibodies directed 
against desmoglein (Dsg) 3 and/or Dsg 1, two trans-
membrane components of desmosomes, and cell-
cell adhesion complexes (1).
Pemphigus is a rare disease with an incidence 
range from 0.5 to 32.0 per 1 000 000 in different 
geographic areas and ethnic groups (2). Pemphigus 
vulgaris (PV) and pemphigus foliaceous (PF) are the 
main clinical subtypes of the disease. PV often af-
fects individuals during the fourth and fifth decades 
of life, and its main characteristics are flaccid blisters 
and erosions of the mucous membranes and the skin. 
The most characteristic clinical findings are painful 
erosions and ulcers in the oral mucosa. in contrast, 
scaly crusted erosions with an erythematous base are 
often observed in PF on the seborrheic regions such 
as the face, scalp, chest, and back without mucosal 
involvement (1).
Few prospective data are available about the 
epidemiology of pemphigus. in the Turkish popula-
tion, there is so far only one prospective study, which 
found the yearly incidence of pemphigus to be 2.4 
per 1 000 000 in the Mediterranean region of Turkey 
(3). The aim of this multicenter one-year prospective 
study was to evaluate the incidence, epidemiological, 
clinical, and immunologic features of patients with 
pemphigus in broader Turkey. 
PATIENTS AND METHODS 
Patients, demographic and clinical  
presentation
Patients with a suspected diagnosis of pemphigus 
who had been referred to one of the 33 dermatology 
departments of university or training and research 
hospitals in 20 different provinces from all geograph-
ic regions of Turkey (Figure 1) were prospectively 
enrolled in the study if they had a newly confirmed 
diagnosis of pemphigus and gave informed written 
consent. Data were collected for the patients with 
pemphigus diagnosed for the first time between 1 
June 2013 and 31 May 2014. The study was approved 
by the ethics committee of Akdeniz University. 
The following demographic and clinical data were 
recorded for all patients: sex, age, age at onset, geo-
graphic history, symptoms at onset, symptoms at the 
time of diagnosis, chronology of the symptoms, clini-
cal findings, subtype of disease, severity, and labora-
tory findings. 
The severity of disease was evaluated using the 
Pemphigus Disease Area index (PDAi) which was de-
veloped by the international Pemphigus Committee. 
PDAi has a potential range of 0 to 263 (120 points for 
skin activity, 120 points for mucosal activity, 10 points 
for scalp activity, and 13 points for postinflammatory 
hyperpigmentation (PiH)). The scores are defined for 
different anatomic regions based on the number and 
size of the lesions (4). 
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Figure 1. The provinces of Turkey (numbered and marked with yellow) where the centers our study was conducted in are 
located and the number of recruited patients.
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Diagnosis of Pemphigus 
At least three samples were taken from each pa-
tient to confirm the diagnosis of pemphigus. Two of 
them were skin biopsies for histologic examination 
from lesional skin and for a direct immunofluores-
cence test (DiF) from perilesional skin. Paraffin and 
frozen sections were performed on the skin samples 
for histological examination and DiF, respectively. A 
classical DiF technique was carried out using fluores-
cein-isothiocyanate conjugated polyclonal sheep an-
tihuman-igg, -igA, -igM, -C3, and fibrinogen antibod-
ies. The third sample was serum from blood samples 
for immune serologic examination using the com-
mercially available anti-Dsg1 and anti-Dsg3 eliSA kit 
and/or indirect immunofluorescence test (iiF). The 
diagnosis of pemphigus (Figure 2) was based on five 
criteria: (i) typical clinical presentation with mucosal 
and cutaneous blisters and erosions for PV or scaly 
crusted erosions and flaccid blisters without mucosal 
involvement for PF; (ii) histopathological evidence of 
intraepidermal blistering with acantholysis; (iii) igg 
deposits on the surface of epidermal keratinocytes 
(PV, PF) and at the dermal-epidermal junction (PnP/
PAMS, Pe) of perilesional skin by DiF microscopy; (iv) 
presence of circulating igg autoantibodies binding 
to the cytoplasmic membrane of stratified epithelia 
(normal human skin or monkey esophagus epithe-
lium); and/or (v) serological detection of anti-Dsg3 
and/or anti-Dsg1 igg autoantibodies by a commer-
cially available eliSA test (euroimmun, luebeck, ger-
many). The presence of (i) and (ii) in addition to either 
(iii), (iv), or (v) were mandatory for the establishment 
of a diagnosis of a new case of pemphigus. 
Statistical analysis
Using data for the Turkish population provided 
by Turkish Statistical institute (http://www.turkstat.
gov.tr), we calculated the mean incidence with their 
95% confidence interval (Ci). Twenty provinces are 
listed below in alphabetical order: Adana, Afyon, 
Ankara, Antalya, Aydın, Bursa, Diyarbakır, elazığ, Ha-
tay, istanbul, izmir, Kayseri, Kocaeli, Konya, Malatya, 
Mersin, Rize, Trabzon, Sivas, Van. in the study period, 
2013-2014, the mean Turkish population consisted of 
77 181 884 persons, of whom 46 382 628 were inhab-
itants of those 20 provinces. The incidence was de-
fined and computed as the number of patients with 
a newly confirmed diagnosis of pemphigus in this 
particular year divided by the total number of inhab-
itants of those 20 provinces.
Statistical analysis was performed on SPSS 16.0 
software. Constant variables in the data set were ex-
pressed as mean, median, Standard Deviation, and 
minimum and maximum values, while categorical 
variables were expressed as frequency and percent-
age.
RESULTS
Patients, demographic, and epidemiologi-
cal data
in total, 252 patients were initially included in 
this multicenter one-year prospective study. Thirty-
two patients who were diagnosed with pemphigus 
without DiF or eliSA were excluded from the final 
analysis. A total of 220 patients, including 129 (58.6%) 
women and 91 (41.4%) men, with a female/male ratio 
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Total of 252 
patients 
32 patients excluded
* Diagnosis without DiF/iiF or eliSA
Positive	DIF	and	positive	ELISA:	98	(44.5	%)
220 patients with Pemphigus 
Positive DiF and consistent clinical features: 210 (95.4 %) Consistent clinical features and positive eliSA: 10 (4.6 %) 
Figure 2. Flow chart of study methods with diagnostic criteria for pemphigus
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of 1:1.41, were studied (Table 1). The mean incidence 
of pemphigus was 4.7 new cases per million people 
per year (95% confidence interval (Ci) 4.1-5.4).
The age range of the onset of the disease was 20-
96 years (mean ± Standard Deviation: 48.92±15.02). 
All patients were older than 20 years of age. The mean 
time period between the onset of the disease and the 
definite diagnosis was 6.45±8.32 months. The short-
est time to diagnosis was 5.87±7.17 months for PV, 
and the longest was 12.35±15.06 for PF. 
Sex ratio and age distribution
There was a female predominance with a male 
to female ratio of 1:1.41. The mean age of onset 
was 48.92±15.02. Patients with PV had a younger 
age of onset than patients with PF (48.13±14.36 vs. 
51.85±19.77). Men were approximately 1 year young-
er than women (48.86±14.17 vs. 49.97±15.99).
Clinical subtypes
Pemphigus vulgaris was the most common clini-
cal subtype, identified in 192 patients (87.3%), with 
an approximately 9-fold higher incidence than PF. 
Pemphigus foliaceus was diagnosed in 21 patients 
(9.6%). The other subtypes were rarely diagnosed, as 
shown in Table 1.
Clinical presentations
Oropharyngeal mucosa was the most common 
site of onset (54.1%) in pemphigus. in 118 (61.4%) 
patients with PV, persistent oral ulcers and erosions 
were the onset manifestations; the skin involvement 
occurred with an average lag period of 3.06±4.62 
months. in 9 (4.6%) patients with PV, oropharyngeal 
mucosa and skin were both involved simultaneously 
at the onset. in 63 patients (32.8%) with PV and all 
patients with PF, pemphigus erythematosus (Pe), 
pemphigus herpetiformis (PH), pemphigus vegetans 
(PVg), and drug-induced pemphigus, the onset was at 
the skin and limited only to the skin. larynx involve-
ment with hoarseness was detected in 35 (15.9%) 
patients, 34 of them were diagnosed with PV. The 
conjunctival mucosa was involved in 17 (7.7%) pa-
tients; all of these patients were also diagnosed with 
PV. Regarding nasal involvement, 18 (8.1%) patients, 
all PV, had nasal erosions. in 149 patients (67.7%), the 
number of lesions were more than 10. The mean PDAi 
score of all patients was 28.14±22.21, consistent with 
moderate to severe disease.
Diagnosis
According to diagnostic features, the largest 
group with 210 patients (95.4%) were the patients 
with typical clinical characteristics of pemphigus and 
positive direct iF. ninety-eight patients (44.5%) in this 
group also had positive tests for eliSA. Additionally, 
in 10 patients (4.6%) the diagnosis was established 
with consistent clinical features and positive eliSA.
Regarding eliSA tests, less than half of the pa-
tients had these test results due to clinical limitations. 
More than 90% sera showed anti-Dsg reactivity in the 
PV group; 97% (96 of 98 patients) for anti-Dsg3 and 
91% (89 of 98 patients) for anti-Dsg1. 
Associated diseases, concomitant medica-
tions, and family history
The most significant associated disease was con-
current hypertension in 15 patients (6.8%). Other as-
sociated diseases were diabetes mellitus in 5 patients 
and goiter, asthma, and hyperlipidemia in 3 patients. 
At the time of diagnosis, 13 patients (5.9%) were be-
ing treated with cardiovascular drugs (7 patients with 
angiotensin-converting enzyme inhibitors, 4 patients 
with angiotensin receptor blockers, and 2 patients 
with beta blockers). Two patients were on cepha-
losporins, and one patient was on d-penicillamine. 
Fourteen patients were recorded as using different 
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Table 1. Demographics and clinical features of 
220 patients with pemphigus
Sex (men:women) 1:1.41
Mean age ± SD (year) 49.51±15.24
Age range (years) 20-96
Mean age of onset ± SD (year) 48.92±15.02
Subtype of pemphigus (n, %)
     Pemphigus vulgaris
     Pemphigus foliaceus
     Pemphigus vegetans
     Pemphigus erythematosus
     Paraneoplastic pemphigus
     Pemphigus herpetiformis








Clinical type of pemphigus vulgaris (n, %)
      Mucocutaneous
      Mucosal




location at onset (n, %)
        Oropharyngeal
        Cutaneous




The number of lesions (n, %)
       <3
       3-5
       6-10





Severity of disease (mean PDAi ± SD) 28.14±22.21
The mean time to diagnosis ± SD (month) 6.45±8.32
*SD: Standard Deviation; PDAi: Pemphigus Dis-
ease Area index
185ACTA DERMATOVENEROLOGICA CROATICA
concomitant medications. Four patients (1.8%) had a 
family history of pemphigus. 
DISCUSSION
This is the first study which aims to evaluate the 
rate of incidence of pemphigus in the Turkish popu-
lation in the different geographic regions of Turkey. 
Thirty-three tertiary referral centers for blistering dis-
eases in 20 different provinces from all 7 geographic 
regions of Turkey (8 centers from both the Central 
Anatolia and the Marmara, 6 centers from the Aege-
an, 5 centers from the Mediterranean, 3 centers from 
the eastern Anatolia, 2 centers from the Black Sea, 
and 1 center from the Southeastern Anatolia regions) 
were included in this study to evaluate the rate of in-
cidence of pemphigus in Turkey. As the study encom-
passed more than 60% of the Turkish population in 
20 provinces from all geographic regions, lasted for 
one year prospectively, and involved 33 tertiary refer-
ral centers for the management of blistering disease, 
our results should therefore be reliable and realistic.
We found an incidence rate of 4.7 new cases per 
million people per year (95% Ci 4.1-5.4). This inci-
dence rate is nearly twice as high as previously re-
ported in the Mediterranean region of Turkey by Uzun 
et al. (2.4 new cases per million people per year) as 
the first prospective epidemiologic data from Turkey 
(3). Additionally, a retrospective study from the Ae-
gean region of Turkey had reported a lower incidence 
rate of 1.8 new cases per million people per year (5). 
The higher incidence rate of our study might be ex-
plained by the differences between the geographic 
Table 2. Demographic characteristics and incidence of pemphigus in different countries








Cordel et al. (29) Prospective guadeloupe 15 1.14 53 6.96
Huang et al. (28), a Prospective Taiwan 853 1.3 52.5 4.70
Zaraa et al. (15) Retrospective Tunisia 92 2 50 8.62
Bastuji-garin et al. (33) Retrospective Tunisia 198 4 36.7 6.70
Baican et al. (6) Prospective Romania 68 1.75 53 4.00
Kumar (32) Prospective india 13 2.33 37 (F), 58 (M) 4.40
golusin et al. (34) Retrospective Serbia 51 1.55 55.6 6.60
nanda et al. (27) Retrospective Kuwait 60 0.9 36.5 4.57
langan et al. (3)a Retrospective UK 138 1.93 71 6.80
Michailidou et al, (14)a Retrospective greece (northern) 129 2.25 59.6 8.00
Chams-Davatchi et al. (17) Prospective iran 1209 1.5 42 10.00 (iran)
16.00 (Tehran)
Salmanpour et al. (31) Retrospective iran (Southwestern) 221 1.33 38 6.70
V’lckova-laskoska et al. (8) Retrospective Macedonia 133 1.33 52 4.40
Marazza et al. (10) Prospective Switzerland 7 2.5 62.3 0.60
Bertram et al. (9)a Prospective germany (lower Franconia) 41 - 62 0.50
Hahn-Ristic et al. (35)a Retrospective germany (lower Franconia, 
Mannheim)
14 1.33 - 0.98
Tallab et al. (26) Retrospective Saudi Arabia (Southern) 19 0.45 43.1 1.60
Micali et al. (13) Retrospective italy (eastern Sicily) 84 1.6 56 6.00
Mahe et al. (24) Retrospective Mali 30 4 46.7 2.90
Tsankov et al. (7) Retrospective Bulgaria (Sofia) 74 1.2 72.4 4.70
Bastuji-garin et al. (12) Retrospective France 87 1.2 52 1.70
Hietanen et al. (11) Retrospective Finland 44 1.1 57.5 0.76
Simon et al. (25) Retrospective USA (Connecticut) 12 5 63.6 4.20 (non-Jewish)
32.00 (Jewish)
Pisanti et al. (16)a Prospective israel (Jerusalem) 76 1.62 - 16.10
Uzun et al. (3) Prospective Turkey (Mediterranean) 148 1.35 43 2.40














* F: Female patients; M: Male patients
a. Studies including only patients with pemphigus vulgaris 
b. Twenty provinces in different geographic regions
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regions (the Mediterranean or the Aegean regions 
vs. all seven geographic regions of Turkey) and our 
broader study design, or by an increase in the rate of 
pemphigus incidence in Turkey. More precisely, our 
new incidence rate for Turkey is closer to reality, by 
covering the all Turkish regions and most of the Turk-
ish population.
Several, mostly retrospective studies (Table 2) 
have been published on the incidence of pemphigus 
in different populations. The incidence of pemphigus 
in Turkey is similar to the countries of South-eastern 
europe such as Romania (6), Bulgaria (7), and Mace-
donia (8) (4, 4.4, and 4.7 new cases per million people 
per year, respectively) and higher than the ones in 
Central and northern europe, such as germany (9), 
Switzerland (10), Finland (11), France (12) (0.50, 0.60, 
0.76, 1.70 new cases per million per year, respective-
ly). The incidence rate of pemphigus in our study is 
lower than the incidence in the countries around the 
Mediterranean Sea, such as eastern Sicily (13), greece 
(14), Tunisia (15), and israel (16) (6.00, 8.00, 8.62, and 
16.10 new cases per million people per year, respec-
tively) and iran (17) (10 new cases per million people 
per year). 
The large variation in the incidence rate of pem-
phigus in different countries suggests the presence 
of various risk and predisposing factors including 
genetic background and environmental factors, such 
as foods or other lifestyle factors (18,19). Certain hu-
man leucocyte antigen (HlA) class ii alleles are more 
prevalent in patients with pemphigus than in the 
general populations. Previous studies have demon-
strated that HlA alleles DRB1*0402 and DQB1*0503 
are positively associated with PV in multiple popula-
tions (20-22). These HlA antigens seem to have cer-
tain roles in the susceptibility to pemphigus through 
the development of an autoreactive T-cell response 
to desmogleins in patients carrying these haplotypes 
(23). it is notable that the incidence rate of pemphi-
gus in Turkey is consistent with the geographical lo-
cation of our country, between South-eastern europe 
and the Mediterranean area.
Regarding sex differences, there was a female 
predominance with a female/male ratio of 1.41 in 
our population. This observation is quite similar with 
most of the reported studies on pemphigus epidemi-
ology. This ratio is generally between one and two, as 
in our study. in some studies, it even reaches four or 
five (24,25). interestingly, the studies with male pre-
dominance with a female/male ratio of 0.45 and 0.9 
were only reported in Saudi Arabia (26) and Kuwait 
(27), respectively. 
The age of our patients ranged from 20-96. The 
overall mean age was 49.5 years. This finding is very 
similar with the data from the past 50 years reported 
in the studies from Macedonia (8), Romania (6), France 
(12), Tunisia (15), Taiwan (28), Mali (23), and guade-
loupe (29). The reported mean ages of the patients 
with pemphigus are generally higher in the studies 
from Central and northern europe (9,10,30) and low-
er in studies from Asian countries like iran and india 
(17,31,32) (Table 2). According to common subtypes, 
the mean ages were 48.4 and 54.8 for PV and PF, re-
spectively. Additionally, the mean ages of onset were 
48.1 and 51.8 for PV and PF. in some endemic areas for 
PF such as Tunisia, the onset of the disease was much 
earlier, generally in the thirties especially in women, 
probably due to traditional lifestyle factors (12,33).
PV was the most common clinical subtype (192 
patients, 87.3%) with a striking nine-fold higher in-
cidence than PF in Turkish population. This result is 
very similar with the ratios of the studies from Medi-
terranean or Aegean regions of Turkey (3-5), 83.1% 
and 93.1%, respectively. These results in the Turkish 
population were also consistent with data of most of 
the reports from european, Mediterranean, or Asian 
countries. According to the results of some studies 
from mostly tropical regions like Tunisia (33) or gaud-
eloupe (29), PF seems to be the most prevalent type 
of pemphigus. interestingly, Pe was reported as the 
most frequent subtype in Finland in an earlier study 
(11).
Regarding clinical characteristics, painful and 
persistent oropharyngeal erosions or ulcers were the 
presenting sign of the disease in most of the patients 
(54.1%). Additional mucosal involvements, includ-
ing larynx involvement with hoarseness (35 patients, 
15.9%), nasal involvement with bleeding (18 patients, 
8.1%), and conjunctival involvement (17 patients, 
7.7%) were observed mostly in patients with PV. The 
frequencies of those involvements in our study were 
remarkably higher than the results of the first pro-
spective study of the Mediterranean region of Turkey 
(3). The mucocutaneous type of PV was the most fre-
quent subtype (83 patients, 43.2%) in the PV group. 
The rate of mucosal PV (69 patients, 35.9%) was very 
close to that rate, in accordance to the well-known 
feature of the PV with mucosal onset.
The association of pemphigus with other diseases 
at the time of diagnosis was generally not investi-
gated in other prospective studies. in our study, the 
most significant associated disease was hypertension 
(15 patients, 6.8%), and 13 patients (5.9%) were being 
treated with cardiovascular drugs, mostly angioten-
sin-converting enzyme inhibitors, at the time of di-
agnosis. Cardiovascular diseases and related medica-
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tions were also the leading associations in the study 
from Switzerland (10) and guadeloupe (29). Other as-
sociated diseases were diabetes mellitus in 5 patients 
and goiter, asthma and hyperlipidemia in 3 patients. 
Our study had some limitations. Firstly, regarding 
recruitment, although 33 tertiary referral centers for 
blistering diseases in 20 different provinces from all 7 
geographic regions of Turkey were included this one-
year prospective study, we cannot be certain that we 
included all newly-diagnosed patients with pemphi-
gus in this study period due to the fact that our study 
did not involve all the dermatology clinics in the entire 
country. The lack of a central registry for autoimmune 
blistering disease makes this impossible at present. 
However, considering the complex and life-threat-
ening nature of the disease, cases may have been 
referred to our tertiary centers which are the main re-
ferral centers for blistering diseases in those regions. 
Because of this limitation, the incidence rate that we 
found may be defined as the minimal incidence rate 
of 4.7 per million people per year. Second, as a one-
year prospective study and consistent with our main 
goals, we were not able to focus on the treatment of 
the patient and the rate of mortality among, which 
could be an important part of studies on pemphigus 
epidemiology.  
CONCLUSION
The findings of this first nationwide epidemiologic 
study indicate that the rate of pemphigus incidence 
in Turkey is similar to the countries of South-east eu-
rope, higher than those reported for the Central and 
northern european countries, and lower than in the 
countries around the Mediterranean Sea and iran. 
Considering the genetic and environmental factors 
predisposing to pemphigus, it may be interpreted as 
a result consistent with the geographical location of 
Turkey between South-eastern europe and the Medi-
terranean area. 
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